Actos Bests Avandia in New Study

GlaxoSmithKline's diabetes drug Avandia faces renewed reports of cardiac risks, while Takeda's Actos appears to reduce such risks

Already under attack for potential heart risks, the diabetes drug Avandia is taking fresh hits from two new studies published Sept. 11 in the Journal of the American Medical Association.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.